Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study: a discrete choice experiment.
Christel ProtièreMichael ArnoldMarion FiorentinoLisa FressardJean D LelièvreMohamed MimiFrançois RaffiMarion MoraLaurence MeyerLuis Sagaon-TeyssierDavid ZucmanMarie PréauOlivier LambotteBruno SpireMarie Suzan-Montinull nullPublished in: Journal of the International AIDS Society (2020)
Severe SE, not outcomes, was the most decisive attribute determining future HCRCT participation. Particular attention should be paid to providing clear information, in particular on severe SE, to potential participants. Immunotherapy would appear to be the best HCRCT candidate for both PLWH and physicians. However, if the risk of cancer could be avoided, gene therapy would become the preferred strategy for the latter and the second choice for the former.
Keyphrases
- gene therapy
- primary care
- clinical trial
- early onset
- antiretroviral therapy
- papillary thyroid
- hiv positive
- decision making
- hiv infected
- human immunodeficiency virus
- working memory
- hiv testing
- physical activity
- hiv aids
- drug induced
- phase ii
- study protocol
- health information
- randomized controlled trial
- metabolic syndrome
- men who have sex with men
- double blind
- human health
- insulin resistance
- social media